Version 2 2020-09-21, 20:37Version 2 2020-09-21, 20:37
Version 1 2020-07-02, 18:13Version 1 2020-07-02, 18:13
figure
posted on 2020-09-21, 20:37authored byTina Costacou, Amy K. Saenger, Trevor J. Orchard
Objective: High-sensitivity cardiac
Troponin-T (hs-cTnT) and N-terminal pro B-Type natriuretic peptide (NT-proBNP),
biomarkers of cardiovascular disease (CVD) and heart failure, respectively,
have not been widely studied in type 1 diabetes (T1D). We evaluated whether their assessment in T1D enhances the
prediction of CVD and major atherosclerotic cardiovascular events (MACE).
<p> </p>
<p>Research Design and Methods: hs-cTnT and NT-proBNP were analyzed on the Roche Cobas
E601 utilizing the first available stored specimen (n=581; mean age 29
and duration 21 years). CVD was defined
as CVD death, myocardial
infarction, coronary revascularization, angina, ischemia, or stroke and MACE as CVD death, myocardial
infarction, or stroke.</p>
<p> </p>
<p>Results: Median hs-cTnT (5.0 ng/L, IQR: <3.0, 10.0) was higher among men
(p<0.0001), whereas median NT-proBNP (22.0 ng/L; 7.0, 61.0) did not differ by sex. In Cox models, log hs-cTnT (HR=1.38, p=0.0006) and log NT-proBNP (HR=1.24, p=0.0001) independently
predicted CVD during 21 years of follow-up.
However, their addition to models either singly or together did not
significantly improve CVD prediction.
Furthermore, a marginally significant sex interaction was
observed (p=0.06), indicating that hs-cTnT’s prediction was limited to men.
hs-cTnT and NT-proBNP also predicted MACE, although only NT-proBNP remained significant
(HR=1.27, p=0.0009) when the biomarkers were included in a model simultaneously. Nonetheless, their addition to multivariable models
did not enhance MACE prediction.</p>
<p> </p>
<p> </p>
<p>Conclusions: Sex differences were observed in the
concentration and predictive ability of hs-cTnT and NT-proBNP in T1D. Overall, their addition to traditional risk factor models increased
the area under the curve for neither CVD nor MACE.</p>
Funding
This research was supported by NIH grant number DK34818 and the Rossi Memorial Fund. The assays for hs-cTnT and NT-proBNP were provided by Roche Diagnostics Corporation. Roche Diagnostics Corporation had input in neither the analysis of data nor the interpretation of results.